Close Menu
Computing.net
    Facebook X (Twitter) Instagram
    Computing.netComputing.net
    • News
      1. AI
      2. Crypto
      3. Gaming
      4. Hardware
      5. Security
      6. Software
      7. View All

      Anthropic’s COBOL Automation Tool Triggers IBM Stock Plunge and Crypto Market Decline

      February 24, 2026

      AI Trading Bot Loses $441K in Crypto After Decimal Point Mistake

      February 23, 2026

      Tesla (TSLA) Stock: Goodbye Sedans, Hello Robots in Dramatic Production Shift

      January 29, 2026

      Palantir Technologies (PLTR) Stock: Why Bears May Be Wrong About Valuation Concerns

      January 29, 2026

      SUI Token Rallies 40% Following Major Staking Event and CME Futures Announcement

      May 12, 2026

      Chainlink (LINK) Surges to $10.40 as Network Activity Hits Eight-Month Peak

      May 12, 2026

      Dogecoin Whales Ramp Up Accumulation as DOGE Eyes Critical Breakout Levels

      May 12, 2026

      Bitcoin Holds $81K While Burry Flags Nasdaq Bubble and Oil Surges Past $105

      May 12, 2026

      Hamster Kombat: Unraveling TON’s Gaming Phenomenon

      August 7, 2024

      W-Coin: Exploring the Latest Telegram Tap-to-Earn Phenomenon

      August 7, 2024

      Hamster Kombat: 300 Million Players & Counting, HMSTR Token Airdrop Soon!

      July 31, 2024

      Hamster Kombat Developers Work with TON Team on Airdrop Solution

      July 30, 2024

      Nothing Expands Product Line with New AI Feature & Phone Update

      July 31, 2024

      Security Audit Reveals Concerns in Atari’s Blockchain Game on Base

      August 6, 2024

      SideWinder Group Targets Maritime Facilities in New Cyber Espionage Campaign

      July 30, 2024

      OAuth Implementation Flaw Exposes Millions of Websites to XSS Attacks

      July 30, 2024

      Hamster Kombat Players Face Growing Cybersecurity Threats

      July 25, 2024

      Anthropic’s COBOL Automation Tool Triggers IBM Stock Plunge and Crypto Market Decline

      February 24, 2026

      Cookie Crumble: Google Halts Plans to Eliminate Third-Party Cookies in Chrome

      July 23, 2024

      Big Brother is Watching: Apple’s Creepy New Ad Urges iPhone Users to Ditch Chrome

      July 23, 2024

      Nvidia Stock Soars to New Record at $219.44 Ahead of May 20 Earnings

      May 12, 2026

      Rocket Lab Shares Surge Past $120 Following Wave of Analyst Upgrades

      May 12, 2026

      GM Shares Decline Following 600 IT Layoffs Amid Strategic AI Workforce Transformation

      May 12, 2026

      SES Delivers €847M Q1 Performance as Intelsat Integration and Aviation Deals Fuel Expansion

      May 12, 2026
    • How To

      Batch Files: Tokens and Delimiters (FOR Loops)

      July 31, 2024

      Types of Ethernet Cabling & Electrical Low Voltage Wiring

      July 9, 2024

      What You Should Know About .JSON File Extension

      January 10, 2023

      Bkup File Extension

      November 19, 2022

      HEIC File Extension

      November 19, 2022
    • Office
      1. Excel
      2. Google Sheets
      3. View All

      How to Convert Column List to Comma Separated List in Excel

      July 24, 2024

      How to Find the Last Monday of the Month in Excel

      July 24, 2024

      Convert Bytes to MB or GB in Excel: 3 Methods!

      July 24, 2024

      How to Remove Characters from Right in Excel

      July 30, 2023

      How to Subtract in Google Sheets: Complete Guide

      July 31, 2024

      Bullet Points in Google Sheets

      January 20, 2022

      Sort by Date in Google Sheets

      January 18, 2022

      Google Sheets Timestamp

      January 17, 2022

      How to Subtract in Google Sheets: Complete Guide

      July 31, 2024

      How to Convert Column List to Comma Separated List in Excel

      July 24, 2024

      How to Find the Last Monday of the Month in Excel

      July 24, 2024

      Convert Bytes to MB or GB in Excel: 3 Methods!

      July 24, 2024
    • Answers
    • About
    • Contact
    Facebook X (Twitter)
    Computing.net
    Stocks

    Corcept Therapeutics Shares Soar 40% on FDA Approval of Lifyorli for Resistant Ovarian Cancer

    Oliver DaleBy Oliver DaleMarch 25, 2026
    Twitter LinkedIn Email Telegram
    Twitter LinkedIn Email Telegram

    Contents:

    Toggle
    • Key Highlights
    • Clinical Trial Results
    • Safety Profile and Adverse Events

    Key Highlights

    • FDA grants approval for Lifyorli (relacorilant) targeting platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
    • Shares of CORT climbed approximately 40% following Wednesday’s announcement
    • Regulatory review concluded 2.5 months before the target completion date
    • Trial results demonstrated median overall survival of 16 months compared to 11.9 months with monotherapy
    • Company maintains a market capitalization near $3.97 billion with consensus analyst price target at $66.80

    Corcept Therapeutics received FDA clearance Wednesday for relacorilant, marketed as Lifyorli, marking a significant milestone for the biopharmaceutical company. The regulatory approval covers use alongside nab-paclitaxel for adult patients diagnosed with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.


    CORT Stock Card
    Corcept Therapeutics Incorporated, CORT

    Shares experienced a dramatic surge of roughly 40% following the announcement, representing one of the most substantial single-session advances in the biotechnology sector during 2023.

    The approved indication targets patients who have completed one to three previous systemic treatment courses, with at least one regimen including bevacizumab. This represents a defined but clinically significant group within a particularly challenging cancer category.

    The regulatory agency wrapped up its evaluation 2.5 months before the scheduled goal date. Early completion of this magnitude remains uncommon and typically indicates compelling evidence in the submitted clinical data.

    Clinical Trial Results

    The regulatory decision stemmed from findings in the ROSELLA trial, a multicenter investigation enrolling 381 participants. Study design allocated half of participants to receive relacorilant combined with nab-paclitaxel, while the remaining half received nab-paclitaxel as monotherapy.

    The combination regimen achieved median progression-free survival of 6.5 months against 5.5 months for standalone therapy. Overall survival reached 16 months with the dual approach versus 11.9 months for nab-paclitaxel alone.

    While these improvements appear incremental, they carry substantial weight in a clinical scenario where treatment alternatives remain scarce. Platinum-resistant ovarian cancer presents significant therapeutic challenges, making any demonstrable survival advantage noteworthy.

    Relacorilant functions through glucocorticoid receptor antagonism. The prescribed regimen calls for 150 mg administered orally once daily across three consecutive days surrounding each nab-paclitaxel infusion.

    Nab-paclitaxel administration follows an 80 mg/m² intravenous schedule on days 1, 8, and 15 within each 28-day treatment cycle.

    Safety Profile and Adverse Events

    Prescribing information identifies contraindications for individuals requiring corticosteroids for critical medical purposes. Frequently observed adverse reactions encompass reduced hemoglobin and neutrophil counts, fatigue, nausea, diarrhea, lowered platelet levels, rash, and diminished appetite.

    From a financial perspective, the organization presents a varied profile. Revenue expanded 22.3% across the previous three-year period. Net margin registers at 13.09% while gross margin reaches a robust 98.3%.

    Earnings growth, however, contracted 33.3% during the past twelve months. The price-to-earnings multiple stands at 45.49, positioning it toward the upper range.

    Balance sheet metrics appear favorable — current ratio measures 2.92 with debt-to-equity ratio at merely 0.01.

    Institutional investors hold 72.18% of outstanding shares. The consensus analyst valuation target reaches $66.80, implying additional upside potential beyond Wednesday’s advance.

    Corcept’s Altman Z-Score registers 14.14, indicating strong financial stability. The Beneish M-Score at -2.81 suggests low probability of accounting manipulation.

    The 50-day moving average prior to Wednesday stood at $37.32, while the RSI reading of 41.26 showed the stock remained below overbought territory before the rally.

    Share. Twitter LinkedIn Email Telegram
    Oliver Dale
    • Website
    • X (Twitter)
    • LinkedIn

    Editor-in-Chief of Computing.net and founder of Kooc Media, A UK-Based Online Media Company. Believer in Open-Source Software, Blockchain Technology & a Free and Fair Internet for all. His writing has been quoted by Nasdaq, Dow Jones, Investopedia, The New Yorker, Forbes, Techcrunch & More. Contact Oliver@blockonomi.com

    Related Posts

    Nvidia Stock Soars to New Record at $219.44 Ahead of May 20 Earnings

    May 12, 2026

    Rocket Lab Shares Surge Past $120 Following Wave of Analyst Upgrades

    May 12, 2026

    GM Shares Decline Following 600 IT Layoffs Amid Strategic AI Workforce Transformation

    May 12, 2026

    SES Delivers €847M Q1 Performance as Intelsat Integration and Aviation Deals Fuel Expansion

    May 12, 2026

    Trump Dismisses Iran Peace Proposal — Oil Markets React as Hormuz Remains Restricted

    May 12, 2026

    Roaring Kitty’s Deleted Posts Trigger Wild GameStop Stock Swings

    May 12, 2026
    Add A Comment

    Comments are closed.

    Latest

    Nvidia Stock Soars to New Record at $219.44 Ahead of May 20 Earnings

    May 12, 2026

    Rocket Lab Shares Surge Past $120 Following Wave of Analyst Upgrades

    May 12, 2026

    GM Shares Decline Following 600 IT Layoffs Amid Strategic AI Workforce Transformation

    May 12, 2026

    SES Delivers €847M Q1 Performance as Intelsat Integration and Aviation Deals Fuel Expansion

    May 12, 2026

    Trump Dismisses Iran Peace Proposal — Oil Markets React as Hormuz Remains Restricted

    May 12, 2026
    • Facebook
    • Twitter

    Latest Reviews

    Meta Platforms Shares Tumble 8% Despite Strong Q1 Performance Amid AI Investment Surge

    April 30, 2026

    Flush.com Review: Casino & Sportsbook With 275% Welcome Bonus

    March 7, 2026

    Katsubet Review: Crypto Casino With 300% Welcome Bonus & Free Spins

    March 7, 2026

    7Bit Review: Crypto Casino With 325% Bonus & 250 FS

    March 7, 2026

    Mega Dice Review: Crypto Casino With 200% Bonus & 50 Free Spins, Legit?

    March 7, 2026


    Home / Privacy Policy / Terms & Conditions

    Computing.net © 1996 - 2026 Kooc Media Ltd. All rights reserved. Registered Company No.05695741

    Type above and press Enter to search. Press Esc to cancel.